恒生港股通创新药精选指数的编算方法调整 相关链接 金十数据7月21日讯，据恒生指数公告，恒生港股通创新药精选指数的编算方法将有以下更新：修改选 股范畴，流动性和行业要求；删除主题和基本因子要求；修改成份股挑选方法以及调整比重上限。此新 编算方法将于截至2025年6月30日之指数检讨时生效，而相关的成份股变动将于2025年9月8日（星期 一）实施。 ...

Group 1 - The calculation method for the Hang Seng Hong Kong Stock Connect Innovative Drug Index will be updated [1] - New liquidity requirements will be added to the index calculation method [1] - Industry requirements will be modified, and thematic requirements will be removed [1] - The method for selecting constituent stocks will be revised [1] - These changes will take effect during the index review as of June 30, 2025, with constituent stock changes implemented on September 8, 2025 [1]

Group 1 - The Hang Seng Biotechnology Index will undergo updates in its calculation methodology, including new requirements for the Stock Connect trading eligibility and modifications to the selection criteria [1] - The number of constituent stocks in the Hang Seng Biotechnology Index will be fixed at 30 [1] - The listing history requirement will be removed, and a rapid inclusion mechanism will be introduced [1] Group 2 - The Hang Seng Hong Kong-US Biotechnology Index will also see updates, with the number of constituent stocks fixed at 40 [1]